Clinical Trial Update: Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired Infants [Phase 2]

View source ↗

Summary

Phase 2 randomized controlled trial evaluating valganciclovir for CMV-infected infants with hearing impairment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infection Causing Congenital Sensorineural Hearing Loss
• Sensorineural Hearing Loss Due to Cmv

Drugs mentioned

• Valganciclovir (Valganciclovir)

Snippet

Sponsor: Albert Park | Conditions: Cmv Congenital, CMV | Phase 2 | Status: ACTIVE_NOT_RECRUITING